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INTRODUCTION {#sec1-1}
============

Skeletal muscle has been recognized as an essential source of progenitor or satellite cells, which are primarily responsible for muscle regeneration\[[@ref1]\]. Satellite cells were first identified by Alexander Mauro in the skeletal muscle of adult frogs in 1961\[[@ref2]\], and they have been referred to by many authors as muscle stem cells. These cells are myogenic precursors that are capable of regenerating skeletal muscle, and they demonstrate self-renewal properties; however, the cells are considered to be committed to the myogenic lineage. Though also isolated from skeletal muscle, muscle-derived stem cells (MDSCs) are to be distinguished from satellite cells. MDSCs may represent a predecessor of satellite cells, and MDSCs are considered different in that they may not be restricted to myogenic or mesenchymal tissues\[[@ref3]\].

MDSCs have been proven to be excellent carriers of therapeutic genes. Thus, MDSCs have been genetically modified with both viral and nonviral vectors that encode for different cytokines and growth factor genes to improve the stem cells' functional characteristics in terms of survival, engraftment, and differentiation\[[@ref4][@ref5][@ref6][@ref7]\].

MDSCs possess a high myogenic capacity, and they effectively regenerate both skeletal and cardiac muscle. Remarkably, when genetically modified *in vitro* to express growth factors, these cells can differentiate into osteogenic and chondrogenic lineages, and they have been shown to promote the repair of bone and cartilage\[[@ref8][@ref9]\]. With regard to hematopoietic differentiation, muscle-derived cells transplanted into lethally irradiated mice have been shown to reconstitute the hematopoietic system\[[@ref10][@ref11]\].

MDSC-based regenerative therapy and tissue engineering using *in vitro* gene therapy are promising approaches for the treatment of various musculoskeletal, cardiovascular, and urological disorders, such as muscular dystrophy, myocardial infarction, and stress urinary incontinence\[[@ref12][@ref13][@ref14]\]. Recent studies have shown that MDSCs may exert an effect on peripheral nerve repair, though details of the mechanisms here await further investigation\[[@ref15][@ref16]\].

In this study, we performed a bibliometric analysis based on the Web of Science (published by the Institute for Scientific Information) to identify the broad patterns in global research and improve the assessment of research trends in MDSC research over the past 10 years.

DATA SOURCES AND METHODOLOGY {#sec1-2}
============================

Design {#sec2-1}
------

A bibliometric study.

Time and setting {#sec2-2}
----------------

The study was carried out in the Jinzhou Clinical College of Liaoning Medical University, Jinzhou Central Hospital in November 2011.

Data retrieval {#sec2-3}
--------------

In this study, we used bibliometric methods to quantitatively and qualitatively investigate research trends in MDSC studies. For this purpose, we employed the Web of Science, a research database of publications and citations that is selected and evaluated by the Institute for Scientific Information in Philadelphia, PA, USA. For bibliometric analyses, we searched the Web of Science using the key words "muscle-derived stem cells" or "MDSCs" or "MDSCs." We limited the period of publication from 2002 to 2011 in compiling a bibliography of all articles related to MDSCs. We searched 802 results, and we downloaded the data on November 20, 2011.

Inclusive criteria {#sec2-4}
------------------

The inclusion criteria were as follows.

\(1\) Peer-reviewed articles on MDSCs that were published and indexed in the Web of Science, including original research articles, reviews, meeting abstracts, proceedings papers, book chapters, editorial material, and news items. The year of publication was 2002--2011 (inclusive). The citation databases were as follows: Science Citation Index-Expanded (SCI-E), 1899--present; Conference Proceedings Citation Index-Science (CPCI-S) 1991--present; Book Citation Index-Science (BKCI-S), 2005--present.

\(2\) Projects on MDSCs actively supported by the National Institutes of Health (NIH).

\(3\) Clinical trials on MDSCs were included.

a\) Web of Science: We included articles from following databases: Social Sciences Citation Index (SSCI), 1898--present; Arts & Humanities Citation Index (A&HCI), 1975--present; Conference Proceedings Citation Index -- Social Science & Humanities (CPCI-SSH), 1991--present; Book Citation Index--Social Sciences & Humanities (BKCI-SSH), 2005--present; Current Chemical Reactions (CCR-EXPANDED), 1985--present; and Index Chemicus (IC), 1993--present.

b\) NIH: The NIH is an agency of the U.S. Department of Health and Human Services and is the primary agency of the U.S. government agency responsible for biomedical and health-related research. Its science and engineering counterpart is the National Science Foundation. The NIH devotes 10% of its funding to research within its own facilities (intramural research). It gives 80% of its funding in research grants to extramural (outside) researchers. The extramural funding consists of about 50 000 grants to more than 325 000 researchers at over 3 000 institutions. Research Portfolio Online Reporting Tools provides access to reports, data, and analyses of NIH research activities, including information on NIH expenditures and the results of NIH-supported research. We included projects on MDSCs that were supported by the NIH from 1988 to the present.

Exclusive criteria {#sec2-5}
------------------

\(1\) Web of Science: We excluded articles that required manually searching or telephone access. We excluded documents that were not published in the public domain. We excluded a number of corrected papers from the total number of articles analyzed.

\(2\) NIH: We excluded publications relating to MDSCs that were supported by the NIH. We limited the keyword search to studies that included MDSCs within the title or abstract.

(3)ClinicalTrials.gov: Clinical trials often involve patients with specific health conditions who then benefit from receiving otherwise unavailable treatments. In early phases, participants are healthy volunteers who receive financial incentives for their inconvenience. During dosing periods, study subjects typically remain on site at the unit for durations of anything from 1 to 30 nights, occasionally longer, although this is not always required. In this study, ClinicalTrials.gov was used to analyze the research trends, which is run by the U.S. National Library of Medicine at the NIH and is the largest clinical trials database, currently holding registrations from over 124 717 trials from more than 170 countries in the world. We included all clinical trials dealing with MDSCs on the ClinicalTrials.gov database. We excluded clinical trials that were not registered on the ClinicalTrials.gov database. We also excluded clinical trials in ClinicalTrials.gov that dealt with stem cells other than MDSCs.

The results from the Web of Science, Research Portfolio Online Reporting Tools (RePORT) of the NIH, and Clinical Trials.gov were exported and analyzed in MS Excel. The outcomes of all articles referring to MDSC studies were measured using the following criteria: (a) type of literature on MDSCs included in the Web of Science from 2002 to 2011; (b) annual publication output on MDSCs included in the Web of Science from 2002 to 2011; (c) journal publications on MDSCs included in the Web of Science from 2002 to 2011; (d) distribution of publications on MDSCs in the Web of Science from 2002 to 2011 by subject area; (e) publications on MDSCs in the Web of Science from 2002 to 2011according to country; (f) publications on MDSCs in the Web of Science from 2002 to 2011 by institution; (g) top published authors of studies on MDSCs in the Web of Science from 2002 to 2011; (h) the most cited papers on MDSCs in the Web of Science from 2002 to 2011; (i) projects on MDSC research funded by the NIH; (j) trials on MDSCs sponsored by the NIH, other federal agencies, and private industry in ClinicalTrials.gov on.

RESULTS {#sec1-3}
=======

The different types of publication relating to MDSCs that were included in the Web of Science from 2002 to 2011. {#sec2-6}
----------------------------------------------------------------------------------------------------------------

From [Table 1](#T1){ref-type="table"}, it is evident that articles, reviews, and meeting abstracts constituted the major types of publication relating to MDSCs over this period. There were 579 articles, accounting for 74.439% of the total number of publications, which was more than for any other type of literature; these were followed by reviews (117), which accounted for 14.589%.

###### 

Types of publication on muscle-derived stem cells included in the Web of Science from 2002 to 2011

![](NRR-7-784-g001)

The annual publication output on MDSCs in the Web of Science from 2002 to 2011 ([Figure 1](#F1){ref-type="fig"}) {#sec2-7}
----------------------------------------------------------------------------------------------------------------

![Annual number of publications on muscle-derived stem cells in the Web of Science from 2002 to 2011.](NRR-7-784-g002){#F1}

There were 802 publications on MDSC studies in the Web of Science from 2002 to 2011. The number of publications on MDSCs has gradually increased over the past 10 years. In all, 152 papers were published and included in the Web of Science in 2011, which was much more than in 2002. However, there was a decrease in the number of papers published in 2005. The journals that published MDSC studies and were included in the Web of Science from 2002 to 2011 are presented in [Table 2](#T2){ref-type="table"}.

###### 

Top 10 journals that published studies on muscle-derived stem cells included in the Web of Science from 2002 to 2011

![](NRR-7-784-g003)

From [Table 2](#T2){ref-type="table"}, it is evident that most of the papers on MDSCs appeared in journals with a particular focus on cell research. *Experimental Cell Research* published 22 papers, which accounted for 2.743% of the total number of publications; this was followed by the *Journal of Cell Science* and *PLoS One*, both of which published 18 papers and accounted for 2.244%. Information relating to the top three journals appears in [Table 3](#T3){ref-type="table"}.

###### 

Details of the top three journals on muscle-derived stem cells included in the Web of Science from 2002 to 2011

![](NRR-7-784-g004)

*Experimental Cell Research* publishes papers in the field of cell and molecular biology, and those papers must provide novel and significant insights into important problems in those areas. The journal\'s areas of interest include, but are not restricted to the following: apoptosis and programmed cell death; cancer research; cell cycles; cell proliferation and differentiation; cellular motility and migration; cell-cell and cell-matrix interaction; chromatin; chromosome structure and dynamics; the cytoskeleton; developmental biology; DNA repair; epigenetics; the extracellular matrix; gene regulation; intracellular trafficking; mammalian genetic models; meiosis and mitosis; microRNA; nuclear import-export; RNA processing; signal transduction; stem cell biology; *etc*. *The Journal of Cell Science* covers all topics in cell biology. Articles have to present a significant hypothesis that provides novel perspectives and approaches to understanding cell biology, and they should stimulate the interest of the journal\'s broad readership. *The Journal of Cell Science* does not publish purely descriptive articles on the expression of specific genes or proteins in particular cell types. It does not present articles that demonstrate the effect of a particular substance on a given cell line without having any broad biological significance and it does not feature articles that simply describe a method or reagent.

*PLoS One* features original research reports from all disciplines of science and medicine. By not excluding papers on the basis of subject area, *PLoS One* facilitates the discovery of the connections both within and between disciplines.

The distribution of subject areas related to MDSCs included in the Web of Science from 2002 to 2011 {#sec2-8}
---------------------------------------------------------------------------------------------------

In [Table 4](#T4){ref-type="table"}, it is evident that among the subject categories related to MDSCs, the greatest number of studies (273 papers) was in the field of cell biology, which accounted for 34.040%. With 107 papers, the second-highest number of studies was in the field of biochemistry and molecular biology, which accounted for 13.342%.

###### 

Distribution of subject areas related to muscle-derived stem cells included in the Web of Science from 2002 to 2011

![](NRR-7-784-g005)

The distribution of publications on MDSCs in the Web of Science from 2002 to 2011 according to country {#sec2-9}
------------------------------------------------------------------------------------------------------

In [Table 5](#T5){ref-type="table"}, it is clear that the United States published the most number of papers on MDSCs; it published 389 papers, which accounted for 48.504% of the total. That is much higher than the number in other countries: Japan ranked second with 76 papers and accounted for 9.476%; China and Italy published 56 papers and ranked joint third. The most cited publications from China included in the Web of Science from 2002 to 2011 are presented in [Table 6](#T6){ref-type="table"}.

###### 

Top 10 countries in terms of number of studies on muscle-derived stem cells included in the Web of Science from 2002 to 2011

![](NRR-7-784-g006)

###### 

The most cited publications from China on muscle-derived stem cells included in the Web of Science from 2002 to 2011

![](NRR-7-784-g007)

The number of publications on MDSCs in the Web of Science from 2002 to 2011 according to institution {#sec2-10}
----------------------------------------------------------------------------------------------------

In [Table 7](#T7){ref-type="table"}, it is evident that the top institution for studies on MDSCs is the University of Pittsburgh, followed by the Children\'s Hospital of Pittsburgh.

###### 

Top 10 institutions publishing studies on muscle-derived stem cells in the Web of Science from 2002 to 2011

![](NRR-7-784-g008)

The University of Pittsburgh is a state-related research university. The University of Pittsburgh frequently ranks as one of the top research universities in the United States.

The most cited papers on MDSCs in the Web of Science from 2002 to 2011 ([Table 8](#T8){ref-type="table"}) {#sec2-11}
---------------------------------------------------------------------------------------------------------

###### 

Most cited papers on muscle-derived stem cells in the Web of Science from 2002 to 2011

![](NRR-7-784-g009)

The top authors in studies on MDSCs in the Web of Science from 2002 to 2011 {#sec2-12}
---------------------------------------------------------------------------

In [Figure 2](#F2){ref-type="fig"}, the most prolific author was Johnny Huard of the University of Pittsburgh.

![Top 10 authors of studies on muscle-derived stem cells included in the Web of Science from 2002 to 2011.](NRR-7-784-g010){#F2}

The most cited papers of Johnny Huard relating to MDSCs included in the Web of Science from 2002 to 2011 are presented in [Table 9](#T9){ref-type="table"}.

###### 

The six most cited papers by Johnny Huard on muscle-derived stem cells in the Web of Science from 2002 to 2011

![](NRR-7-784-g011)

In literature metrology, one of the main criteria of a paper\'s quality is the number of citations. It is an important index of how peer scholars assess the academic value of a publication. The more frequently a paper is cited, the greater will its influence grow. If a paper is cited four or more times a year, it can be regarded as a "classic paper." In the present study, six papers were cited more than 200 times over the last 10 years, which allows them to be identified as classic papers on MDSCs. In 2002, there were three classic papers. Two classic papers appeared in both 2004 and 2005. In 2009, another classic paper was published. During this period, the development of MDSCs emerged as a hot area of international study.

RePORT was used to investigate how MDSC studies are supported by the NIH, including the number of grants provided and the amount of fundings supplied. The supported projects are shown in [Table 10](#T10){ref-type="table"}.

###### 

Projects on muscle-derived stem cells research funded by the NIH

![](NRR-7-784-g012)

The institutes that appear in [Table 10](#T10){ref-type="table"} are all located in the United States. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) promotes basic discoveries, design, development, and translation and assessment of technological capabilities in biomedical imaging and bioengineering using information science, physics, chemistry, mathematics, materials science, and computer sciences. The National Institute of Aging (NIA) conducts a national program in the United States into the biomedical, social, and behavioral aspects of aging as well as the prevention of age-related diseases and disabilities and the promotion of a better quality of life for older individuals. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports research into the causes, treatment, and prevention of arthritis as well as musculoskeletal and skin diseases; it is involved in the training of scientists to carry out this research and in disseminating information on research into these diseases. The National Institute of Dental and Craniofacial Research (NIDCR) promotes a national research program in the United States to understand, treat, and prevent infectious and inherited craniofacial-oral-dental diseases and disorders. The National Heart, Lung, and Blood Institute (NHLBI) leads a national program in the United States into diseases of the heart, blood vessels, lung, and blood, blood resources, and sleep disorders.

Eight projects studying MDSCs have received over US\$6 billion in funding from the NIH. The University of Pittsburgh has received the greatest support in studies related to NIH, particularly those of the university\'s Dr. Huard, who has led three NIH-supported projects in MDSCs. NIBIB, NIA, NIAMS, NIDCR, and NHLBI are administrative institutes of the NIH that plan, conduct, promote, and support integrated and coordinated programs of basic research, clinical investigations and trials, observational studies, and demonstration and education projects in studies related to MDSCs. The only current project supported by the NIH is "Muscle-Based Tissue Engineering to Improve Bone Healing" (Project Number 5R01DE013420-10), led by Dr. Johnny Huard of the University of Pittsburgh. The main goal of the project is the development of tissue-engineering approaches, based on MDSCs, to efficiently deliver osteogenic proteins and improve craniofacial bone healing. The project began in July 2000, and ends in August 2012. In fiscal 2012, the project received \$454 500 from NIDCR. In all, 36 papers have been published as part of the project since 2001. No subprojects or patents have been available under the project.

ClinicalTrials.gov, developed by the Food and Drug Administration of the NIH, offers up-to-date information on locating federally and privately supported clinical trials for a wide range of diseases and conditions. A clinical trial (also known as clinical research) is a research study using human volunteers to answer specific health questions. ClinicalTrials.gov currently contains 124 717 trials sponsored by the NIH, other federal agencies, and private industry. The studies listed in its database are conducted in all 50 states and in 179 countries ClinicalTrials.gov receives over 50 million page views per month 65 000 visitors daily.

The only clinical trial on MDSCs is "Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence (MDC)" Phase 1, which is registered and sponsored by Johns Hopkins University and led by Dr. John P. Gearhart; it began in November 2009. The aim of this study is to study the safety, tolerability, and efficacy of muscle-derived cell therapy in children with bladder exstrophy epispadias induced urinary incontinence.

DISCUSSION {#sec1-4}
==========

Based on our bibliometric results with the Web of Science, we found the following research trends in studies on MDSCs over the past 10 years. In all, 802 publications on MDSC studies were retrieved from the Web of Science from 2002 to 2011, of which almost half the publications derived from American authors and institutes. The number of publications on MDSCs has gradually increased over the past 10 years. Most papers on MDSCs appeared in journals with a focus on cell biology research, such as *Experimental Cell Research, Journal of Cell Science*, and *PLoS One*.

Eight projects in MDSC research have received over \$6 billion in funding by the NIH. The current project led by Dr. Johnny Huard of the University of Pittsburgh---"Muscle-Based Tissue Engineering to Improve Bone Healing"---is supported by the NIH. Dr. Huard is also the most productive and top-cited author in the field of gene therapy and adult stem cell research in the Web of Science over the last 10 years. On ClinicalTrials.gov, there is only one registered trial---"Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence" Phase 1; this is sponsored by Johns Hopkins University and led by Dr. John P Gearhart; it began on November 2009. Much attention and effort has been devoted to peripheral nerve regeneration using cell therapy including MDSCs. The findings of the present study may be of interest to fellow researchers who are currently undertaking studies on MDSCs or those who may do so in the future.
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